← Back
Data updated: Mar 10, 2026
ORYZA
Infectious Disease
ORYZA is a generic drug manufacturer focused on Infectious Disease.
2020
Since
2
Drugs
-
Trials
105
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
DOXYCYCLINE HYCLATE 2026-02-19
DOXYCYCLINE HYCLATE 2026-02-06
Labeling
DOXYCYCLINE HYCLATE 2026-02-06
Labeling
DOXYCYCLINE HYCLATE 2026-01-26
Labeling
DOXYCYCLINE HYCLATE 2026-01-20
Labeling
DOXYCYCLINE HYCLATE 2026-01-20
Labeling
DOXYCYCLINE HYCLATE 2026-01-18
Labeling
DOXYCYCLINE HYCLATE 2025-12-09
DOXYCYCLINE HYCLATE 2025-11-19
DOXYCYCLINE HYCLATE 2025-11-06
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Infectious Disease 100%
1 drugs
Pipeline Strength Pro
Loading...
Active (1)
Discontinued (1)
Company Info
- First Approval
- 2020-04-03
- Latest
- 2025-03-31
- Applications
- 2